Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?
This article was originally published in The Pink Sheet Daily
Executive Summary
If successful, Sanofi-Aventis' attempt to acquire Genzyme would catapult the company into the orphan drug business, marking Big Pharma's most aggressive strategy in the space to date.
You may also be interested in...
Pfizer Adds To Specialty Care Division With Purchase Of FoldRx
Focused on protein misfolding disorders, FoldRx has a lead candidate under review at EMA for transthyretin amyloid polyneuropathy.
Pfizer Adds To Specialty Care Division With Purchase Of FoldRx
Focused on protein misfolding disorders, FoldRx has a lead candidate under review at EMA for transthyretin amyloid polyneuropathy.
Pfizer Increases Commitment To Rare Diseases With New Research Unit
In-licensing and development of so-called "bio-betters" will play critical roles in Pfizer's move, announced June 14, into the rare diseases space. The Rare Diseases Research Unit, to be overseen by Jose Carlos Gutierrez-Ramos, senior VP, Biotherapeutics Research and Development, will be part of Pfizer's worldwide R&D unit devoted to discovering novel medicines for orphan diseases, those affecting fewer than 200,000 patients. Initially it will target hemophilia and muscular dystrophy, both caused by genetic mutations